Investor Presentation H1 2023
49
Investor presentation
First six months of 2023
PIONEER programme with oral semaglutide
PIONEER
1
2
3
4
5
7
Baseline
8.0%
8.1%
8.3%
8.0%
8.0%
8.3%
-0.1
-0.1
-0.1
Change in
HbA1c (%)
-0.5
8
8.2%
-0.6
-0.7
-1.0*
-0.8
-0.8
-0.9
-1.1
-1.1*
-1.3*
*
-1.1
-1.4
-1.3
*
-1.4*
-1.4
-1.5*
88 kg
92kg
91 kg
94 kg
91 kg
89 kg
Baseline
-1.7
-1.5
Change in
weight (kg)
-2.5
-3.8
-4.1*
-4.2
-0.7
*
-1.2
-2.2
-3.3*
-4.7
-0.7
-3.2
-3.7
-1.1
-1.4
*
86 kg
0.6
-0.8
*
-1.3
*
-2.9
*
-3.0
-4.1*
Novo NordiskⓇ
oral semaglutide 3 mg
oral semaglutide 7 mg
oral semaglutide 14 mg
placebo
sitagliptin 100 mg
empagliflozin 25 mg
Victoza 1.8 mg
Note: PIONEER 9 and PIONEER 10 were Japanese studies and PIONEER 6 was a CV safety study. * Statistically significant based on the hypothetical treatment policy; PIONEER 1: QD oral sema vs placebo in people with T2D treated with diet and exercise only;
PIONEER 2: QD oral sema vs empagliflozin 25 mg in people with T2D; PIONEER 3: QD oral sema vs sitagliptin 100 mg in people with T2D; PIONEER 4: QD oral sema vs Victoza® 1.8 mg and placebo in people with T2D; PIONEER 5: QD oral sema vs placebo in people
with T2D and moderate renal impairment; PIONEER 7: QD oral sema using a flexible dose adjustment based on clinical evaluation vs sitagliptin 100 mg in people with T2D; PIONEER 8: Effects of QD oral sema vs placebo in people with long duration of T2D
treated with insulin ER: Extended-release; QW: once-weekly; QD: once-daily; oral sema: oral semaglutide; T2D: type 2 diabetes, OAD: oral anti-diabetics; CV: CardiovascularView entire presentation